The assessment of activated T cells proportions within splenic cells revealed percentages of CD3+/CD137+ T cells in the PBS, Poly IC, routine peptide, and the translatome peptide groups to be 0.25, 0.95, 2.89 and 4.83%, respectively (Fig. 4A), concurrently confirming the marked capability of the translatome-derived neoantigen peptide vaccine to inhibit tumor growth. Here, TNFRSF9 is linked to neoplasm.